References
1] National Institute for Health and Care Excellence. Ovarian Cancer: Recognition and Initial Management. NICE Guidelines CG122. London, UK: National Institute for Health & Care Excellence (NICE),2011.
2] Moore RG, D. McMeekin DS, Brown AK et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology 2009; 112:40–46.
3] Barr CE, Funston G, Jeevan D, et al. The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population. Cancers. 2022; 14:2124.
4] Molina R, Escudero JM, Augé JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biology. 2011;32:1087-95.